Companies /Healthcare

Neoleukin Therapeutics Inc

NASDAQ: NGNE Biotechnology
$23.32
▲ $0.22 (+0.93%) today
Markets open · 3:56pm ET

NGNE at a Glance

Valuation
Market cap
$478.2M
Profitability
EPS (TTM)
$-4.99
Price
52-week range
$16 – $44
Street target
$77.62

Headquartered in New York, NY Fiscal year ends December NASDAQ: NGNE neurogene.com

About Neurogene

Neurogene Inc. (Nasdaq: NGNE) is a clinical-stage biotechnology company that develops genetic medicines for rare, devastating neurological diseases. It has no approved products or product revenue. The company pairs a biology-first design approach with optimized delivery, including its proprietary EXACT transgene regulation technology, which is designed to keep protein expression tightly controlled cell by cell.

Its lead program is NGN-401, an investigational one-time AAV9 gene therapy for Rett syndrome:
- It delivers the full-length human MECP2 gene using a single-stranded AAV construct.
- It is administered by intracerebroventricular injection.
- It is being evaluated in the Embolden registrational trial, where dosing is complete with 25 participants; topline data are expected in the second half of 2027.

NGN-401 holds several regulatory designations:
- FDA: Breakthrough Therapy, RMAT, Fast Track, Orphan Drug and Rare Pediatric Disease designations, plus selection for the START Pilot Program.
- EMA: ATMP, Orphan and PRIME designations.
- UK MHRA: ILAP designation.

Neurogene runs a fully integrated, in-house AAV manufacturing facility in Houston (42,000 sq ft, with 6,000 sq ft of cleanrooms) that supports both HEK293 and Sf9/rBV platforms. It is preparing for a BLA submission and potential commercial launch, targeting an estimated 15,000–20,000 Rett syndrome patients in the US, EU and UK. The company has been reducing spending on its CLN5 Batten disease program. Updated

NGNE Coverage

Frequently Asked Questions

What does Neurogene do?

Neurogene Inc. (Nasdaq: NGNE) is a clinical-stage biotechnology company that develops genetic medicines for rare, devastating neurological diseases. It has no approved products or product revenue.

What is the NGNE stock price target?

The Wall Street consensus 12-month price target for NGNE is $77.62.